Objective:To re-evaluate the clinical efficacy and safety of Longfengbao tablets for the treatment of perimenopausal syndrome. Method: Eighty-four patients were randomly divided into treatment group and control group (n=42 each). The control group was treated with livial 2.5 mg daily; the treatment group was orally given Longfengbao tablets 1.2 g tid. The treatment lasted for 12 weeks. Kupperman score

serum estradiol (E2)

follicle stimulating hormone (FSH)

luteinizing hormone (LH) l

endometrial thickness were measured and traditional Chinese medicine clinical symptom score were compared between the two groups. Result: After the treatment

the two sets of the Kupperman ratings and deficiency syndrome integral were significantly lowered than before (P<0.01)

the deficiency syndrome points of the treatment group was lower than that of the control group(P<0.01). Serum E2 level in two groups was significantly increased after treatment (P<0.01). The effective rate of the treatment group was 88.09% while the control group was 92.85%; the endometrial thickness did not change significantly after the treatment in both groups. The treatment group showed no adverse reactions. Conclusion: Longfengbao tablets can significantly improve the clinical symptoms of perimenopause syndrome

reduce the Kupperman score

elevated serum E2 levels without increasing endometrial thickness

and it is safe and effective.